Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD
Clinical trial NCT05578222 · UNKNOWN
Trial details
- NCT number
- NCT05578222
- Sponsor
- Tianjin Chest Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-10
- Primary completion
- 2023-12-12
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.